Last reviewed · How we verify
NCT04976062: IMPACTavi
NIRS-IVUS to Improve Assessment of Coronary Artery Disease Severity in Patients Referred for Transcatheter Aortic Valve Implantation
trial testing Combined near-infrared spectroscopy and intravascular ultrasound imaging (NIRS-IVUS) in Coronary Artery Disease in 150 participants. Status unknown.
31 December 2024
Quick facts
| Lead sponsor | Deutsches Herzzentrum Muenchen |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 150 |
| Start date | 10 November 2020 |
| Primary completion | 31 December 2024 |
| Estimated completion | 31 December 2024 |
| Sites | 2 locations across Switzerland, Germany |
Drugs / interventions tested
- Combined near-infrared spectroscopy and intravascular ultrasound imaging (NIRS-IVUS)
Conditions studied
- Coronary Artery Disease — all drugs for Coronary Artery Disease →
- Aortic Stenosis, Severe — all drugs for Aortic Stenosis, Severe →
Sponsor
Deutsches Herzzentrum Muenchen — full company profile →
Who can join
18 and older, any sex, with Coronary Artery Disease or Aortic Stenosis, Severe. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of the IMPACTavi prospective cohort study is to test feasibility and safety of clinically indicated intravascular coronary imaging with NIRS-IVUS in addition to routine coronary angiography in patients scheduled for TAVI, to improve assessment of CAD severity in this challenging group of patients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04976062
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Coronary Artery Disease
Currently open trials in the same condition.
- NCT07399002 — LONG NAGOMI™ PMCF STUDY · recruiting
- NCT07420582 — Antegrade Autologous Blood Reinfusion After CPB · recruiting
- NCT07493603 — A Study on Yiyang Huoluo Decoction in the Treatment of Coronary Heart Disease · Phase 1, PHASE2 · recruiting
- NCT06535568 — Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO · NA · recruiting
- NCT07286578 — A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Under · NA · recruiting
Other Deutsches Herzzentrum Muenchen trials
Trials by the same sponsor.
- NCT07344480 — Retrospective Natural History Study of RASopathy-associated Cardiomyopathy (RAS-CM) · recruiting
- NCT06369142 — Intracoronary Stenting and Additional Results Achieved by ShockWAVE Coronary Lithotripsy · NA · recruiting
- NCT06753227 — Invasive Versus Echocardiography-derived Transvalvular Gradients After TAVI Usign Balloon-expandable Transcatheter Heart · enrolling by invitation
- NCT06814574 — Pacemaker Implantation Following Transcatheter Tricuspid Valve Replacement · recruiting
- NCT06060912 — LAmbre Versus AMPLATZER Amulet Left AtrIal Appendage Occluder for StRoke ProphylaxIs · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04976062 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Deutsches Herzzentrum Muenchen
- Last refreshed: 4 November 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04976062.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing